220 related articles for article (PubMed ID: 30346380)
21. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic neoplasms: An overview on diagnosis, risk-stratification, molecular pathogenesis, and treatment.
Marques FK; Sabino AP
Biomed Pharmacother; 2022 Dec; 156():113905. PubMed ID: 36306593
[TBL] [Abstract][Full Text] [Related]
23. Targeting miR-126 disrupts maintenance of myelodysplastic syndrome stem and progenitor cells.
Wang H; Sun J; Zhang B; Zhao D; Tong H; Wu H; Li X; Luo Y; Dong D; Yao Y; McDonald T; Stein AS; Al Malki MM; Pichiorri F; Carlesso N; Kuo YH; Marcucci G; Li L; Jin J
Clin Transl Med; 2021 Oct; 11(10):e610. PubMed ID: 34709739
[TBL] [Abstract][Full Text] [Related]
24. Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Slade M; DiPersio JF; Westervelt P; Vij R; Schroeder MA; Romee R
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1736-1743. PubMed ID: 28688919
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
26. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
27. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
28. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.
Pang WW; Czechowicz A; Logan AC; Bhardwaj R; Poyser J; Park CY; Weissman IL; Shizuru JA
Blood; 2019 May; 133(19):2069-2078. PubMed ID: 30745302
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
31. [Myelodysplastic syndromes].
Geissler K
Wien Med Wochenschr; 1991; 141(9-10):201-4. PubMed ID: 1949844
[TBL] [Abstract][Full Text] [Related]
32. Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.
Bereshchenko O; Lo Re O; Nikulenkov F; Flamini S; Kotaskova J; Mazza T; Le Pannérer MM; Buschbeck M; Giallongo C; Palumbo G; Li Volti G; Pazienza V; Cervinek L; Riccardi C; Krejci L; Pospisilova S; Stewart AF; Vinciguerra M
Clin Epigenetics; 2019 Aug; 11(1):121. PubMed ID: 31439048
[TBL] [Abstract][Full Text] [Related]
33. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
34. Therapy-related myelodysplastic syndrome.
Candelaria M; Dueñas-Gonzalez A
Expert Opin Drug Saf; 2015 May; 14(5):655-65. PubMed ID: 25675961
[TBL] [Abstract][Full Text] [Related]
35. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
36. [Prognosis and Therapy of Myelodysplastic Syndrome].
Bonadies N
Ther Umsch; 2022; 79(2):93-105. PubMed ID: 35291847
[TBL] [Abstract][Full Text] [Related]
37. [Myelodysplastic syndromes--an overview for the practitioner].
Solenthaler M; Tobler A
Ther Umsch; 2004 Feb; 61(2):117-24. PubMed ID: 15018394
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic syndromes.
Utley SM
Semin Oncol Nurs; 1996 Feb; 12(1):51-8. PubMed ID: 8650442
[TBL] [Abstract][Full Text] [Related]
39. [Recent advances in therapy of myelodysplastic syndromes].
Hu QJ; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1522-5. PubMed ID: 23257466
[TBL] [Abstract][Full Text] [Related]
40. Quercetin induces autophagy in myelodysplastic bone marrow including hematopoietic stem/progenitor compartment.
Daw S; Law S
Environ Toxicol; 2021 Feb; 36(2):149-167. PubMed ID: 32902906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
